Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Captor Therapeutics S.A.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06994572CT.gov Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT04803318CT.gov Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT02973204CT.gov Circulating Tumor Cells and Tumor DNA in HCC and NET | — | Completed | — | — | — |
NCT02081755CT.gov Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer | — | Enrolling By Invitation | — | — | — |
NCT01379521CT.gov Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC | — | Terminated | — | — | — |
NCT01035229CT.gov Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. | — | Completed | — | — | — |
NCT00688753CT.gov RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe | — | Completed | — | — | — |
NCT00828594CT.gov Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT00719264CT.gov Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer | — | Completed | — | — | — |
NCT00775073CT.gov Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001 | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT00516165CT.gov RAD001 in Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00390195CT.gov Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC) | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Everolimus (this asset) | Captor Therapeutics S.A. | Approved | BB · 64 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Everolimus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuberous Sclerosis | — | P3 | BBB · 76 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 75 |
| Hodgkins Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Everolimus in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/everolimus-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →